Conference · London, United Kingdom
Late Phase Drug Development World Europe 2010
Pharmaceuticals · Life Sciences
Key numbers
- Editions on record
- 3first in 2010
About Late Phase Drug Development World Europe
Late phase drug development is growing at around 20% annually, exceeding the growth rate of Phase II and III Trials. In excess of $12 billion is currently being spent on Phase IIIb/IV studies as public concerns on the safety of approved drugs prevail together with the need to evaluate real world safety and effectiveness of marketed drugs. Are you spending this money wisely? More than ever before there is the urgent need to detect, quantify and communicate patient risk with speed and efficiency.
The 2nd annual Late Phase Drug Development World Europe 2010 is the only strategic forum addressing the major challenges in conducting strategic and compliant late stage studies.
From our listing of this edition. Details may have changed since.
Editions
| Year | Dates | Where | Exhibitors | Visitors |
|---|---|---|---|---|
| 2012 | 5–6 Dec 2012 | The Wyndham Grand London Chelsea Harbour London, United Kingdom | — | — |
| 2011 | 6–8 Dec 2011 | Earls Court London, United Kingdom | — | — |
| 2010 | 30 Nov – 3 Dec 2010 | The Bloomsbury Hotel London, United Kingdom | — | — |
Past editions from the bvents archive (2008–2019) and organiser figures where they were published.